Non-advanced group (stage 0 and I) n=24 | Advanced group (stage II A–IV B) n=18 | p Value | |
---|---|---|---|
Gender (male/female) | 17/7 | 11/7 | 0.741 |
Age (year) (median) | 53 | 50.5 | 0.023 |
Disease duration (year) (median) | 13 | 24.5 | 0.284 |
Extensive colitis (%) | 16 (66.7) | 17 (94.4) | 0.055 |
Family history of CRC | 1 (4.2) | 2 (11.1) | 0.387 |
Concomitant PSC (%) | 1 (4.2) | 1 (5.5) | 0.834 |
Medication | |||
Duration of treatment with 5-ASA (%) | |||
Naïve | 1 (4.2) | 2 (11.1) | 0.489 |
Within 1 year | 0 (0) | 2 (11.1) | |
From 1 to 5 years | 5 (20.8) | 0 (0) | |
From 6 to 10 years | 4 (16.7) | 2 (11.1) | |
Over 10 years | 11 (45.8) | 12 (66.7) | |
Unknown | 3 (12.5) | 0 (0) | |
Duration of treatment with CS (%) | |||
None | 4 (16.7) | 7 (38.9) | 0.458 |
Within 1 year | 6 (25.0) | 2 (11.1) | |
Over 1 year | 10 (41.7) | 7 (38.9) | |
Unknown | 4 (16.7) | 2 (11.1) | |
Dose of CS (g) median (range) | 4.3 (1.79–17.0) | 16.15 (2.3–30) | 0.28 |
Immunomodulator use (%) | 8 (33.3) | 4 (22.2) | 0.657 |
Anti TNF-α agents use (%) | 3 (12.5) | 1 (5.6) | 0.623 |
NSAIDs use (%) | 1 (4.2) | 2 (11.1) | 0.567 |
Time to previous colonoscopy (months) (median) | 13 | 16 | 0.735 |
5-ASA, 5-aminosalicylic acid; CRC, colorectal cancer; CS, corticosteroid; NSAIDs, non-steroidal anti-inflammatory drugs; PSC, primary sclerosing cholangitis; TNF-α, tumour necrosis factor-α.